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Abstract
Background: Neurofibromatosis type 1 (NF1) is a common dominant tumor predisposition syndrome affecting 1 in
3,500 individuals. The hallmarks of NF1 are the development of peripheral nerve sheath tumors either benign
(dermal and plexiform neurofibromas) or malignant (MPNSTs).
Results: To comprehensively characterize the role of microRNAs in NF1 tumorigenesis, we analyzed 377 miRNAs
expression in a large panel of dermal and plexiform neurofibromas, and MPNSTs. The most significantly upregulated
miRNA in plexiform neurofibromas was miR-486-3p that targets the major tumor suppressor gene, PTEN. We confirmed
PTEN downregulation at mRNA level. In plexiform neurofibromas, we also report aberrant expression of four miRNAs
involved in the RAS-MAPK pathway (miR-370, miR-143, miR-181a, and miR-145). In MPNSTs, significant deregulated
miRNAs were involved in PTEN repression (miR-301a, miR-19a, and miR-106b), RAS-MAPK pathway regulation (Let-7b,
miR-195, and miR-10b), mesenchymal transition (miR-200c, let-7b, miR-135a, miR-135b, and miR-9), HOX genes
expression (miR-210, miR-196b, miR-10a, miR-10b, and miR-9), and cell cycle progression (miR-195, let-7b, miR-20a,
miR-210, miR-129-3p, miR-449a, and miR-106b).
Conclusion: We confirmed the implication of PTEN in genesis of plexiform neurofibromas and MPNSTs in NF1.
Markedly deregulated miRNAs might have potential diagnostic or prognostic value and could represent novel
strategies for effective pharmacological therapies of NF1 tumors.
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Background
Neurofibromatosis type 1 (NF1) is a common autosomal
dominant disorder affecting 1 in 3,500 individuals world-
wide. Typical clinical features of NF1 include multiple
café-au-lait spots, axillary freckling, iris Lisch nodules,
and neurofibromas. Neurofibromas are benign periph-
eral nerve sheath tumors designated as either dermal
neurofibromas (DNFs) or plexiform neurofibromas (PNFs).
PNFs are regarded as congenital benign tumors that often
develop in association with major nerve tracts. About
30 to 50% of NF1 patients develop clinically visible
PNFs [1]. Although PNFs are considered as benign
tumors, they can be life threatening when they develop
deeply and compress internal organs. PNFs are complex
tumors, heterogeneous at the cellular level, mainly com-
posed of Schwann cells, which are the likely pathogenic
cell type in neurofibromas, together with fibroblasts,
mast cells, neurons, vascular elements, and perineurial
cells. In contrast to DNFs, PNFs can transform in malig-
nant peripheral nerve sheath tumors (MPNST) in about
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10% of the cases. MPNSTs are highly invasive sarcomas
that metastasize widely and display a poor prognosis.
NF1 is caused by germline heterozygous loss-of-function
mutations in the tumor suppressor gene NF1 located at
17q11.2. NF1 encodes neurofibromin, a RAS-GTPase-acti-
vating protein (RAS-GAP). Neurofibromin negatively reg-
ulates the RAS signalling pathways (i.e. MAPK and PI3K/
AKT/mTOR) involved in proliferation, survival, and
differentiation. According to the Knudson’s two-hit model,
NF1 tumorigenesis results from a somatic mutation
disrupting the second functional copy of the NF1 gene.
This complete inactivation of NF1 induces RAS signaling
pathway activation and seems required but not sufficient
for tumorigenesis promotion. Rare additional molecular
alterations have been described in PNFs, including
CDKN2A/B locus deletions [2]. In contrast, MPNSTs
are characterized by complexe genomic changes including
inactivation of TP53 and RB1 and amplification of EGFR,
HGF, and MET [3]. Expression studies have reported
differential expression profile in MPNSTs of genes in-
volved in cell proliferation, apoptosis, invasion, extracellu-
lar remodeling and Schwann cell differentiation such as
TP53, RB1, CDKN2A, TWIST1, BIRC5, TOP2A, and SOX9
[4-6]. Finally, transgenic mouse models have provided evi-
dences for TP53 and PTEN implication in PNFs formation
and Schwann cells malignant transformation [7,8].
Since their initial discovery in Caenorhabditis elegans
in 1993 [9], the highly conserved small non-coding RNAs
called microRNAs (miRNAs) have been extensively impli-
cated in human physiology and pathology. In the last few
years, miRNAs have revealed major roles in regulating
critical biological processes such as development, prolifer-
ation, differentiation, and apoptosis. MiRNAs aberrant
expression has also been characterized in many human
cancer types. However, the involvement of miRNAs de-
regulation in the formation of benign neurofibromas and
malignant progression from PNFs to MPNSTs remains
largely unknown. Here, we used real-time quantitative
reverse transcription-PCR (RT-PCR) assays to quantify the
expression of a panel of 377 well-validated miRNAs in a
large series of NF1-associated tumors (including nine
DNFs, 41 PNFs, and 15 MPNSTs), two normal peripheral
nerve samples, and two MPNSTcell lines.
Results
We quantified the expression of 377 miRNAs in nine
DNFs, 41 PNFs, and 15 MPNSTs. We also analyzed
miRNAs expression in two adult peripheral nerves as a
non-tumorigenic control tissue and in two MPNST cell
lines (ST88.14 and 90–8) as malignant controls. A signifi-
cant number (122/377; 32.4%) of miRNAs were below the
detection level of the assay (median Ct ≥ 40) in MPNSTs,
PNFs, and DNFs and were consequently regarded as
“not expressed”. Eighty-four (84/377; 22.3%) miRNAs
were considered as detectable but not reliably quantifi-
able (32 <median Ct < 40) in the three groups of tumors.
Thereby, more than half of miRNAs (206/377; 54.6%)
were not further analyzed in our study. In each sample,
the negative control assay unrelated to mammalian spe-
cies, ath-miR159a, was not expressed (Ct ≥ 40).
Unsupervised hierarchical clustering
Unsupervised hierarchical clustering of the 65 NF1-
associated tumors, two adult peripheral non-tumorigenic
control nerves, and the two NF1-associated MPNST cell
lines identified six main subgroups, based on the expres-
sion of the 171 miRNAs considered as expressed and re-
liably quantifiable. One of the subgroup contained 12 of
the 15 MPNST samples together with both MPNSTs cell
lines (88–14 and 90.8) and no other tumor types. The
three remaining MPNST samples (MPNST2, MPNST7,
and MPNST9) clustered in a small subgroup of six tumors.
Our unsupervised hierarchical clustering discriminated
MPNSTs from benign neurofibromas but failed to distin-
guish between both types of neurofibromas (i.e. between
DNFs and PNFs). This result mainly reflects that miRNAs
expression profile is more deregulated in MPNSTs than in
benign neurofibromas.
Comparison of miRNAs profile between DNFs and PNFs
DNFs and PNFs are both benign nerve stealth tumors
but PNFs can undergo malignant transformation, in con-
trast to DNFs. Hence, we first compared miRNAs expres-
sion between DNFs and PNFs. MiRNAs were considered
as significantly differentially expressed between DNFs and
PNFs when the P-value of the non-parametric comparison
Mann–Whitney test was less than 0.05 (P < 0.05). Eleven
miRNAs met these criteria and were considered as
displaying a markedly different expression between
DNFs and PNFs (Table 1). Among these 11 miRNAs,
ten were upregulated (fold changes ranged from 1.76 to
8.57) and only one (miR-203) was downregulated (fold
change = 0.13) in PNFs as compared to DNFs. The only
downregulated miRNA in PNFs compared to DNFs
(miR-203) has previously been described to be silenced
in various types of malignancies.
Comparison of miRNAs profile between PNFs and
MPNSTs
One hundred thirteen miRNAs were differentially ex-
pressed between PNFs and MPNSTs (P < 0.05): 103 were
upregulated (Additional file 1: Table S3) in MPNSTs and
10 were downregulated (fold changes ranged from 0.19 to
0.61; Table 2). We observed high statistical significant
upregulation (P < 0.00001) of 28/103 upregulated miRNAs
in MPNSTs compared to PNFs (fold changes ranged from
2.4 to 2616.7; Table 2).
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Hierarchical clustering
To identify a miRNA signature that could be a useful
adjunct to NF1-associated tumor diagnosis, a hierarchical
clustering was performed. Hierarchical clustering of the
nine DNF and 41 PNF samples, based on the expression
of the 11 significantly deregulated miRNAs between those
two types of tumors (Table 1) identified two main groups
of tumor samples with exclusively PNFs in one group
(P = 0.0055; Figure 1). Both peripheral nerve samples
(PN1 and PN2) clustered in the DNFs-containing sub-
group. We also selected the 38 most strongly deregulated
miRNAs between PNFs and MPNSTs (Table 2) to perform
a hierarchical clustering of these two types of tumors.
Analysis of the dendrogram based on the expression of
those 38 miRNAs allowed us to identified two main
groups, with 98% of PNFs (40/41) clustered in one group
and 80% of MPNSTs (12/15) in the other group (P < 10-7;
Figure 2). Interestingly, MPNSTs cell lines clustered with
the MPNSTs-containing subgroup.
Coregulation of physically clustered miRNAs
We hypothesized that clustered miRNAs (i.e. located at
the same locus) may function as a single transcription
unit. Among upregulated miRNAs in MPNSTs compared
to PNFs (Table 2; Additional file 1: Table S3), we identified
several clustered miRNAs: miR-301b and miR-130b are
located in 22q11.2, miR-301a and miR-454 are located in
17q22 in the first intron of the SKA2 gene, miR-224 and
miR-452 are located in Xq28 inside the GABRE gene,
miR-106b and miR-93 are located in 7q22 within intron
13 of the MCM7 gene, and miR-19a, miR-18a, miR-20a,
and miR-19b belong to the polycistronic cluster miR-17 ~
92 located in 13q31.3. Similarly, among the miRNAs
upregulated in PNFs compared to DNFs (Table 1), miR-
143 and miR-145 belong to the same cluster located in
5q32. A Spearman’s rank correlation test demonstrated
that miR-301b and miR-130b (r = +0.67, P = 3.1.10-6),
miR-301a and miR-454 (r = +0.48, P = 1.7.10-3), miR-224
and miR-452 (r = +0.77, P = 7.6.10-8), miR-106b and miR-93
(r = +0.84, P < 10-8), and miR-143 and miR-145 (r = +0.90,
P < 10-8) have positive correlated expression. In addition,
we showed that both miR-224 (Spearman’s rank correlation
coefficient = +0.49, P = 0.002) and miR-452 (r = +0.47, P =
0.002) have positive correlated expression with their host
gene, GABRE.
Coregulation of paralogous miRNAs
We hypothesized that paralogous miRNAs may target
the same protein-coding genes, acting as synergistic
co-regulators of shared target genes. Among the most
significantly upregulated miRNAs in MPNSTs compared
to PNFs (Table 2), two couples of paralogous miRNAs
differ in only few base pairs: miR-301a and miR-301b
(targeting NF1), and miR-10a and miR-10b (targeting
PTEN). Using a Spearman test, we demonstrated that
expression of miR-301a and miR-301b (r = +0.65, P =
6.7.10-6), and miR-10a and miR-10b (r = +0.75, P = 1.5.10-7)
have significantly positive correlated expression. These
paralogous miRNAs have high sequence identity but are
located at different loci and chromosomes. Their correlated
Table 1 List of the significantly deregulated miRNAs in plexiform neurofibromas relative to dermal neurofibromas
miRNAs Functionally
verified
gene target(s)
Location Host
gene
Dermal neurofibromas
(n = 9)
Plexiform neurofibromas
(n = 41)
Fold
changea
P
b Peripheral
nerves (n = 2)c
Significantly upregulated miRNAs in plexiform neurofibromas relative to dermal neurofibromas
miR-486-3p PTEN [10] 8p11.2 ANK1 1.3 [0.03-12.8]d 9.3 [0.02-198.0] 7.41 0.002 1.4 [0.90-1.8]
miR-185 22q11.2 2.8 [0.10-23.6] 16.0 [0.04-97.5] 5.67 0.003 8.4 [3.1-13.8]
miR-362-5p Xp11.2 CLCN5 4.8 [0.09-72.6] 18.5 [0.03-312.0] 3.90 0.008 21.3 [7.2-35.4]
miR-370 MAP3K8 [11] 14q32.2 13.8 [5.4-33.0] 28.7 [0.08-232.6] 2.08 0.008 11.5 [10.8-12.1]
miR-491-5p 9p21.3 12.8 [2.0-22.1] 22.6 [0.02-115.3] 1.76 0.014 27.6 [23.8-31.3]
miR-143 KRAS [12] 5q32 185.0 [68.1-411.0] 437.7 [3.3-3156.7] 2.37 0.016 426.1 [339.9-512.4]
miR-193a-5p 17q11.2 2.0 [0.58-13.5] 16.9 [0.02-168.9] 8.57 0.017 11.3 [8,0-14.5]
miR-483-5p 11p15.5 IGF2 7.4 [0.27-24.2] 19.7 [0.02-326.9] 2.67 0.020 112.3 [38.7-185.8]
miR-181a KRAS [13] and
ATM [14]
1q32.1 and
9q33.3
NR6A1
(9q33.3)
8.2 [0.71-84.3] 36.3 [0.02-231.0] 4.44 0.022 10.7 [5.7-15.7]
miR-145 RREB1 [15] 5q32 436.3 [259.8-2572.9] 1792.9 [22.9-14808.8] 4.11 0.024 830.3 [688.1-972.4]
Significantly down-regulated miRNA in plexiform neurofibromas relative to dermal neurofibromas
miR-203 14q32.3 36.2 [1.2-10966.7] 4.8 [0.05-2943.7] 0.13 0.010 2.6 [2.3-2.8]
aMedian expression in plexiform neurofibromas/Median expression in dermal neurofibromas.
bMann-Whitney’s U Test.
cNon tumorigenic controls.
dMedian [range] of miRNAs levels.
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Table 2 List of the most significantly deregulated miRNAs in MPNSTs relative to plexiform neurofibromas
miRNAs Functionally
verified target(s)
Localization Host
gene
Plexiform
neurofibromas
(n = 41)
MPNSTs (n = 15) Fold
changea
P
b Peripheral nerves
(n = 2)c
Significantly down-regulated miRNAs in MPNSTs relative to plexiform neurofibromas (n = 10)
miR-139-5p 11q13.4 PDE2A 368.8 [5.6-1523.2]d 71.8 [27.6-247.8] 0.19 < 0.00001 253.1 [149.9-356.3]
miR-150 19q13.3 1910.1 [4.4-6800.1] 529.6 [105.6-3531.6] 0.28 < 0.0001 1573.4 [1428.9-1717.9]
miR-338-3p 17q25.3 AATK 10.7 [0.03-115.4] 2.3 [0.02-29.8] 0.21 < 0.001 125.6 [88.7-162.5]
miR-195 CCND1, CDK6,
E2F3[16] CCNE1
[17] and RAF1
[18]
17p13.1 1689.4 [0.03-9958.6] 503.8 [166.6-2233.1] 0.30 < 0.001 689.6 [633.5-745.7]
miR-146a 5q34 3117.1 [85.4-49237.4] 1252.7 [186.9-
65865.7]
0.40 < 0.001 3705.8 [2932.0-4479.5]
miR-95 4p16.1 ABLIM2 44.5 [0.02-175.7] 26.6 [3.6-56.2] 0.60 0.001 12.7 [7.5-18.0]
let-7b RAS [19], CCND1
[20] and HMGA2
[21]
22q13.3 1642.3 [15.8-12746.3] 543.6 [63.9-1531.6] 0.33 0.003 2777.1 [1011.0-4543.1]
miR-186 1p13.1 ZRANB2 2030.1 [1.6-3193.4] 1240.9 [727.8-7687.8] 0.61 0.003 2303.1 [1717.4-2889.2]
miR-885-5p 3p25.3 ATP2B2 52.4 [0.51-393.3] 20.6 [2.4-62.4] 0.39 0.006 67.2 [46.5-87.9]
miR-200c ZEB1 [22] and
ZEB2
12p13.3 8.4 [0.51-861.1] 4.8 [0.01-22.4] 0.57 0.008 8.1 [6.1-10.0]
Most significantly upregulated miRNAs in MPNSTs relative to plexiform neurofibromas (n = 28)
miR-135b APC [23] 1q32.1 0.41 [0.02-12.0] 1060.9 [4.2-3562.1] 2616.7 < 10-6 3.4 [0.57-6.3]
miR-449a CCND1 and
HDAC1 [24]
5q11.2 CDC20B 0.45 [0.00-11.4] 14.4 [0.28-25.9] 32.30 < 10-6 4.0 [3.4-4.6]
miR-210 HOXA1, HOXA9,
HOXA3, and
E2F3 [25]
11p15.5 9.8 [0.05-254.1] 236.0 [3.2-458.5] 24.00 < 10-6 69.2 [19.0-119.4]
miR-301b PTEN [26] 22q11.2 0.81 [0.02-8.2] 17.3 [1.9-121.6] 21.19 < 10-6 0.20 [0.03-0.37]
miR-301a 17q22 SKA2 8.7 [0.02-87.8] 173.7 [23.0-592.2] 20.04 < 10-6 3.7 [3.3-4.0]
miR-9 CDH1 [27] and
CDX2 [28]
1q22, 5q14.3
and 15q26.1
52.9 [0.03-472.9] 787.6 [2.9-1265.6] 14.90 < 10-6 411.7 [400.8-422.5]
miR-130b 22q11.2 8.3 [0.02-53.5] 66.2 [23.3-442.7] 7.96 < 10-6 7.0 [5.5-8.6]
miR-454 17q22 SKA2 257.3 [0.05-631.7] 1259.4 [494.9-2684.4] 4.90 < 10-6 508.4 [481.2-535.7]
miR-19a PTEN [29] and
CCND1 [30]
13q31.3 201.3 [0.04-764.3] 749.1 [429.9-2078.0] 3.72 < 10-6 146.9 [141.3-152.5]
miR-106b PTEN, CCND1,
and E2F1 [31,32]
7q22.1 MCM7 126.5 [0.05-483.2] 439.2 [233.9-1795.6] 3.47 < 10-6 81.9 [80.1-83.8]
miR-135a APC [23] 12q23.1 and
3p21.1
GLYCTK
(3p21.1)
0.05 [0.01-4.4] 25.7 [0.01-158.3] 537.54 < 0.00001 65.8 [0.02-131.5]
miR-137 1p21.3 0.08 [0.01-40.2] 21.4 [0.07-82.0] 258.68 < 0.00001 17.6 [3.1-32.1]
miR-31 9p21.3 6.4 [0.02-2747.4] 1581.9 [0.02-8261.8] 246.61 < 0.00001 83.0 [13.7-152.4]
miR-129-3p CDK6 7q32.1 and
11p11.2
0.04 [0.00-2.5] 3.8 [0.01-1409.7] 92.36 < 0.00001 0.94 [0.48-1.4]
miR-224 Xq28 GABRE 7.0 [0.04-135.0] 120.2 [8.0-748.0] 17.26 < 0.00001 14.7 [9.6-19.9]
miR-10b NF1, HOXA3 and
HOXD10 [33,34]
2q31.1 49.1 [0.02-832.3] 649.6 [12.4-1640.1] 14.19 < 0.00001 64.8 [11.7-117.9]
miR-148a 7p15.2 50.2 [0.04-450.0] 413.6 [3.8-793.2] 8.24 < 0.00001 8.5 [5.2-11.9]
miR-18a 13q31.3 3.0 [0.02-38.4] 21.2 [6.4-104.6] 7.02 < 0.00001 5.9 [1.4-10.4]
miR-452 Xq28 GABRE 9.9 [0.18-82.0] 58.6 [14.6-260.7] 5.93 < 0.00001 19.5 [19.1-19.9]
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overexpressions in MPNSTs may depend on common
regulation and could reflect a cooperative activity to switch
off shared target genes.
Inverse expression of miRNAs with their protein-coding
gene targets
Using Spearman’s rank correlation test, we reported that
several upregulated miRNAs in MPNSTs compared to
PNFs have significant inverse correlated expression with
their previously identified target genes: HMGA2 mRNA
expression is inversely correlated with let-7b (r = −0.387,
P = 0.003) and PTEN expression is inversely correlated
with miR-301a (r = −0.67, P = 5.9.10-8), miR-19a (r = −0.67,
P = 6.4.10-8), and miR-106b (r = −0.65, P = 1.5.10-7).
Expression of four miRNAs processing machinery
components: DICER, DROSHA, DGCR8 and AGO2
Alterations of miRNAs processing machinery components
expression have been reported in human tumors [36].
We therefore explored the possibility that global miRNA
dysregulation observed in NF1 tumorigenesis could be
due to altered expression of DICER, DROSHA, DGCR8
and/or AGO2, and their expressions were determined.
No significant differences in DICER, DROSHA, DGCR8
and AGO2 mRNA levels were found in PNFs compared
to DNFs or in MPNSTs compared to PNFs (P > 0.01;
Additional file 1: Table S4). These observations reinforce
the specificity of the identified signature (11 deregulated
miRNAs in PNFs and 113 in MPNSTs) versus a global
miRNAome deregulation caused by a tumor alteration of
miRNAs biogenesis.
Discussion
Recent evidences indicate that miRNA network play a
critical role in the regulation of gene expression involved
in tumor development and progression. In this study, we
applied a RT-PCR analysis to comprehensively characterize
the expression pattern of 377 miRNAs in a large series of
benign and malignant NF1-related nerve sheath tumors.
Eleven miRNAs were found to be differentially expressed
between DNFs and PNFs (Table 1). Interestingly, the most
significantly upregulated miRNA in PNFs, miR-486-3p,
targets the major tumor suppressor gene, PTEN [10]. PTEN
expression is frequently decreased in a wide spectrum of
human cancers with several miRNAs being validated as
PTEN regulators [37]. Using murine conditional deletion of
Pten and activation of Kras, Gregorian at al. suggested that
PTEN dosage is critical for formation of PNFs [8]. MiRNAs
regulation typically allows such subtle modulations in gene
expression dosage. It is important to note that the two
tested peripheral nerve samples (non-tumorigenic samples)
showed similar level expression of miR-486-3p than DNF
samples (Table 1). Overexpression of miR-486-3p in PNFs
may therefore specifically reflect an abnormal upregulation
in these tumors. We further hypothesised that miR-486-3p
may be a major onco-miR by downregulating PTEN in
PNFs development.
Our results also reveal overexpression of miR181a in
PNFs. MiR181a targets ATM [14], a tumor suppressor
that regulates the p53 pathway [38] that has been shown
to be essential for PNFs formation in transgenic mouse
models [7]. Similar level expression of miR181a was
found in both peripheral nerve samples and in DNFs
samples (Table 1).
Finally, three other markedly overexpressed miRNAs
in PNFs compared to DNFs have previously been dem-
onstrated to negatively regulate the RAS signaling path-
way: miR-370 targets MAP3K8 [11], miR-143 targets
KRAS [12,13], and miR-145 targets RREB1 [15]. Biallelic
loss of function of the NF1 gene in neurofibromas pro-
motes activation of the RAS signaling pathway. We assume
that overexpression of these four miRNAs may reveal a
feedback loop that attempts to correct hyperactivation
of RAS signaling. Interestingly, miR-143 and miR-145
Table 2 List of the most significantly deregulated miRNAs in MPNSTs relative to plexiform neurofibromas (Continued)
miR-598 8p23.1 XKR6 15.8 [0.04-105.7] 93.3 [5.0-524.7] 5.91 < 0.00001 29.9 [29.0-30.8]
miR-196b HOXB8 [34] 7p15.2 29.7 [0.54-526.4] 165.2 [12.5-788.5] 5.56 < 0.00001 124.9 [70.5-179.3]
miR-425 3p21.3 DALRD3 16.3 [0.11-116.5] 84.4 [38.3-105.1] 5.18 < 0.00001 19.2 [11.5-27.0]
miR-10a HOXD10 [35] 17q21.3 HOXB3 53.1 [0.04-498.1] 230.1 [67.6-400.7] 4.33 < 0.00001 21.3 [14.2-28.3]
miR-93 7q22.1 MCM7 149.2 [0.04-860.2] 607.8 [303.6-2824.3] 4.07 < 0.00001 142.8 [114.4-171.2]
miR-20a CCND1 and E2F1
[31]
13q31.3 295.6 [0.02-1269.4] 1064.2 [196.3-3498.9] 3.60 < 0.00001 531.2 [390.0-672.5]
miR-19b 13q31.3 and
Xq26.2
1757.9 [0.99-5939.3] 4761.9 [2678.3-11811.4] 2.71 < 0.00001 3039.0 [2435.6-3642.5]
miR-484 Xq26.2 1354.6 [70.2-4301.5] 3537.7 [1213.0-8554.1] 2.61 < 0.00001 1047.4 [438.8-1656.1]
miR-192 11q13.1 38.8 [0.02-95.4] 94.3 [39.7-236.6] 2.43 < 0.00001 27.4 [18.7-36.1]
aMedian expression in MPNSTs/Median expression in plexiform neurofibromas.
bMann- Whitney’s U Test.
cNon tumorigenic controls.
dMedian [range] of miRNAs levels.
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are both located at 5q32 and have positive correlated
expressions, suggesting a common transcription unit,
allowing a concerted action on RAS pathway.
We also investigated the 113 differentially expressed
miRNAs between PNFs and MPNSTs. Among the 103
upregulated and the ten downregulated miRNAs in
MPNSTs, we further analyzed the most markedly differen-
tially expressed miRNAs (Table 2). A subset of miRNAs
(miR-301a [26], miR19a [29], and miR-106b [31,32]) previ-
ously demonstrated to directly target the suppressor PTEN
was found to be overexpressed in MPNSTs. Recent
transgenic mice model with Pten and Nf1 conditional
knock out in Schwann cells, implicated the synergistic role
of Pten and Nf1 inactivation in MPNSTs development
[23]. We confirmed that PTEN expression was inversely
correlated with miR-301a, miR-19a, and miR-106b. Inter-
estingly, we showed that paralogs miR-301a and miR-301b
have significantly positive correlated expression suggesting
that these two miRNAs may synergistically target PTEN.
We also identified a panel of five deregulated miRNAs
(miR-135a, miR-135b, miR-9, miR-200c, and let-7b) that
are major regulators of epithelial-mesenchymal transition
P= 0.0055 
22 samples
(0 DNFs, 22 PNFs)
28 samples
(9 DNFs, 19 PNFs, 2 PNs)
Figure 1 Dendrogram of the nine DNFs, 41 PNFs, and two peripheral nerves (PN1 and PN2) constructed using a supervised
hierarchical clustering with UPGMA algorithm according to the expression of the 11 miRNAs significantly deregulated between
DNFs and PNFs.
Masliah-Planchon et al. BMC Genomics 2013, 14:473 Page 6 of 11
http://www.biomedcentral.com/1471-2164/14/473
(EMT). MiR-135b and miR-135a represent the most
overexpressed miRNAs in MPNSTs compared to PNFs
(Table 2). Members of the miR-135 family target the
tumor suppressor APC, a key negative regulator of the
WNT canonical pathway involved in tumorigenesis
[39]. E-cadherin [27] is a major epithelial adherens
junction protein which plays a critical role in EMT.
MiR-9 is also overexpressed in MPNSTs and it has been
previously demonstrated that miR-9 is upregulated in
breast cancer cells and targets the E-cadherin gene (also
named CDH1) [40].
MiR-200c and let-7b are both downregulated in
MPNSTs compared to PNFs. Members of miR-200 family
act as critical regulators of EMT and contribute to the
acquisition of invasive behavior in many types of cancer
[22]. They negatively regulate expression of ZEB1 [19] and
ZEB2, two E-box binding transcription factors that are
powerful regulators of E-cadherin expression and several
P = 10-7
45 samples
(3 MPNSTs, 2 PNs, 40 PNFs)
15 samples
(12 MPNSTs, 2 cell lines)
Figure 2 Dendrogram of the 41 PNFs, 15 MPNSTs, two peripheral nerves and two MPNST cell lines constructed using a supervised
hierarchical clustering with UPGMA algorithm according to the expression of the 28 miRNAs most significantly deregulated between
PNFs and MPNSTs.
Masliah-Planchon et al. BMC Genomics 2013, 14:473 Page 7 of 11
http://www.biomedcentral.com/1471-2164/14/473
other effectors involved in epithelial polarity. Let-7 family
miRNAs regulate cell proliferation and differentiation and
are frequently downregulated in many human cancers
[21]. They are considered as tumor suppressor miRNAs,
notably through targeting genes with oncogenic activity
such as RAS [21] and HMGA2 [41]. We confirmed that
HMGA2 expression is inversely correlated with let-7b.
HMGA2 enhances TWIST (whom expression is regulated
by WNT signaling) and inhibits CDKN2A/CDKN2B
gene expression, corresponding with aggressive behavior
[42-44]. Hyperactivation of RAS signaling pathway,
overexpression of TWIST1 [6] and CDKN2A inactivation
[3] have frequently been reported in MPNSTs. Together,
upregulation of miR-135a, miR-135b, and miR-9 and
downregulation of miR-200c and let-7b in MPNSTs may
thus contribute to mesenchymal transition with acquisi-
tion of an invasive behavior in these malignant aggressive
tumors.
Our results also independently confirm that miR-10b is
significantly upregulated in MPNSTs compared to PNFs.
Expression of miR-10b is induced by the metastasis-
promoting transcription factor TWIST [44]. Chai et al.
previously showed overexpression of miR-10b in MPNSTs
and demonstrated that miR-10b targets NF1 mRNA [44].
MiR-10b controls expression of the pro-metastatic RhoC
via directly targeting HOXD10 mRNA [33]. HOXD10
encodes a homeobox (HOX) protein that act as a tran-
scriptional repressor of RHOC. Aberrant expression of
RHO GTPases or RHO effectors has been described in
various cancer types, suggesting the implication of
RHO signaling pathway in NF1 tumorigenesis [34].
Interestingly, our analysis of miRNAs expression in
MPNSTs revealed a significant upregulation of others
miRNAs that target HOX genes (Table 2): miR-196b
targets HOXB8 [35], miR-210 targets HOXA1, HOXA9,
and HOXA3 [25], miR-10a and miR-10b target HOXA3
and HOXD10 [28], and miR-9 target CDX2 [45]. HOX
genes represent a large group of related genes encoding
transcription factors with crucial roles in development,
apoptosis, differentiation, and cell motility [46].
Among the most markedly differentially expressed
miRNAs in MPNSTs (Table 2), we also identified a panel
of significantly deregulated miRNAs (including miR-195,
let-7b, miR-210, miR-20a, miR-19a, miR-449a, miR-129-3p,
and miR-106b) that target major regulators of cell cycle.
MiR-195 is downregulated in MPNSTs and has recently
been described as a tumor suppressor in various types of
cancers [16]. MiR-195 targets several G1/S transition-
related genes such as cyclin D1 (CCND1), CDK6, E2F3
[17], and CCNE1 [20]. Let-7b (downregulated in MPNSTs,
Table 2) has also been shown to repress CCND1 expres-
sion [30]. In addition miR-210 targets E2F3 [25], miR-20a
targets CCND1 and E2F1 [31], miR-19a and miR-449a
target CCND1 [24], miR-129-3p targets CDK6 [47],
and miR-106b targets CCND1 and E2F1 [31]. Interestingly,
NF1 inactivation has previously been shown to enhance
CCND1 expression in Schwann cells [18]. Overexpression
of CCND1 could thus account for a major feature of
the Schwann cells proliferation in MPNSTs formation.
Moreover, miR-210 has been described as a key regulator
of the hypoxia response in tumor onset identified as a
major HIF1A-induced miRNA, and makes link between
hypoxia and the regulation of cell cycle [25]. We con-
firmed that miR-210 has a significant positive correlated
expression with HIF1A (r = +0.57; P = 5.8.10-6).
A subset of significantly deregulated miRNAs in
MPNSTs (let-7b, miR-195, and miR-10b) has previously
been described to target members of the RAS-MAPK
pathway. Let-7b is a member of the let-7 miRNAs family
which target RAS [21]. Recent data report that miR-195
targets RAF1 [48], a direct downstream effector of RAS.
Interestingly, let-7b and miR-195 are both downregulated
in MPNSTs compared to PNFs and could subsequently
act as indirect activator of the RAS-MAPK pathway.
Additionally, miR-10b is upregulated in MPNSTs and
has been previously demonstrated to target NF1 [44].
Conclusion
In conclusion, miRNAome profiling of NF1-associated pe-
ripheral nerve sheath tumors suggests intricately deregu-
lated associated molecular networks. We identified several
subsets of markedly deregulated miRNAs in PNFs, in par-
ticular miR-486-3p that targets PTEN, a major component
of the RAS-PI3K-AKT signaling pathway. Our work high-
lights the key role of miRNAs in NF1-associated tumori-
genesis, leading to subtle reductions in PTEN levels. Our
result also confirmed the major role of PTEN in MPNSTs
formation. Our study identifies miRNAs clearly deregulated
in MPNSTs and involved in oncogenic events including loss
of cell adhesion and metastatic behavior mediated by EMT,
deregulation of HOX genes expression, increased cell cycle
progression, and RAS-MAPK aberrant signaling. All of
these miRNAs should be further investigated using in vitro
or in vivo experiments to fully understand their role in the
formation of neurofibromas and MPNSTs and to identify
mechanisms involved in their deregulation. Finally, our
results may serve for the basis of potential diagnostic and
predictive biomarkers and represent novel strategies for
effective pharmacological therapies of NF1 tumors.
Methods
Patients and samples
Tissue samples of nine DNFs, 41 PNFs, and 15 MPNSTs
were obtained after surgical excision from NF1 patients
followed in the Neurofibromatosis National Reference
Center (Henri Mondor Hospital, Créteil, France). Tumors
classification was confirmed at the histological level by our
NF1 reference pathologist (N.O.). Main characteristics of
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the 15 studied patients with MPNST are presented in
Additional file 1: Table S1. Immediately after excision,
tumor samples were frozen in liquid nitrogen and stored
at −80°C. All of the patients fulfilled the national institute
of health (NIH) diagnostic criteria for NF1. Adult sciatic
and tibial nerves from two different control subjects with
no NF1 were also analyzed (Department of Orthopedic
Surgery, Cochin Hospital, Paris, France). The study was
approved by the local ethics committee and all the partici-
pants gave their written informed consent. Two MPNST
cell lines established from NF1 patients (ST88-14 and
90–8) were kind gifts from Pr. Nancy Ratner (Cincinnati
Children's Hospital Medical Center, USA).
RNA extraction
Total RNA was extracted from frozen tumor samples,
MPNSTs cell lines, and fresh adult nerves by using the
acid-phenol guanidinium method. The quantity of the
RNA samples was assessed with a Nanodrop spectropho-
tometer (Coleman Technologies, Orlando, FL). The qual-
ity of the RNA samples was determined by electrophoresis
through agarose gels and staining with ethidium bromide.
MiRNAs expression analysis
Reverse transcription reaction was performed using the
TaqMan MicroRNA Reverse Transcription Kit (Applied
Biosystems, Foster City, CA) according to the manufac-
turer’s instructions. Taqman primers for the miRNA arrays
(Megaplex RT Human Pool A) were used for reverse tran-
scription and thermal cycling was performed over 40 cycles
(16°C for 2 min, 42°C for 1 min, 50°C for 1 s), after which
the reactions were held at 85°C for 5 min and then at 4°C.
Expression of 377 miRNAs from the Sanger database v12
(Additional file 1: Table S2) was subsequently analyzed in
all the samples using the 384-wells microfluidic TaqMan
Low Density Array (Applied Biosystems TaqMan human
microRNA cardA v2.0 composed of 384 single assays
including 377 highly characterized human miRNAs) based
on stem-loop real-time PCR based TaqMan miRNA expres-
sion assay. Each sample was normalized on the basis of its
miR-191 content. We selected miR-191 as endogenous con-
trol because this miRNA is known to be one of the most
stably expressed miRNAs across different normal and
tumor tissues [49]. Cycle threshold (Ct) values were
obtained using the SDS software v2.3 set with automatic-
baseline. Each result was determined as a difference in tar-
get miRNA expression relative to miR-191 and expressed
as 2ΔCt. This value of the samples was subsequently norma-
lized such that a sample with a Ct of 32, considered as the
limit of quantification of the system, showed a value of 1.
Protein-coding genes real-time RT-PCR
We quantified the mRNA level of the following genes: four
genes encoding components of the miRNAs biogenesis
pathway (DICER, DROSHA, DGCR8 and AGO2), three
miRNAs host genes (SKA2, GABRE, and MCM7), two
miRNAs target genes (PTEN and HMGA2), and one
known inducer of miR-210 (HIF1A). The practical aspects
of real-time quantitative RT-PCR using the ABI Prism
7900 Sequence Detection System (Applied Biosystems)
have been described in detail elsewhere [50]. Briefly, each
sample expression was normalized on the basis of its
content of an endogenous control gene (TBP, TATA box
binding protein) and such that the median expression in
the DNFs values was 1. The nucleotide sequences of the
oligonucleotide primers used to amplify the different
target genes are available on demand.
Clustering and statistical analysis
As miRNA expression levels did not fit a Gaussian distri-
bution, (i) miRNA levels in each group of tumors were
expressed as their median values rather than their mean
values and (ii) comparisons of each miRNA between tu-
mors groups were tested by using the non parametric
Mann–Whitney U test. Clustering was performed using the
UPGMA (Unweighted Pair Group Method with Arithmetic
Mean) hierarchical algorithm with GeneANOVA software.
We performed a chi-square test to statistically compare the
tumors distribution in hierarchical clustering. We applied
Spearman correlation test to identify pairs of miRNAs
with similar expression patterns and correlated expres-
sion between miRNAs and protein-coding genes.
Availability of supporting data
The data set supporting the results of this article are
included within the article and its Additional file 1.
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